Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59®‐adjuvanted influenza vaccine in older adults: Results from three consecutive seasons

摘要

In Europe, the enhanced safety surveillance (ESS) of seasonal influenza vaccines is mandatory, in order to detect any potential increase in reactogenicity when the vaccine composition is updated. The MF59 ‐adjuvanted influenza vaccine (Fluad™) is the first and the only licensed adjuvanted seasonal influenza vaccine in Europe.